Company profile
HOME - LIGHTOX
Illuminating therapeutics & research tools. LightOx are developing new therapeutic solutions to improve patients function and long-term outcomes with oral cancer. We have a unique range of molecular tools for use in imaging, therapeutics and assay development.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
CS01 | Transaction MzQzMjc3MTAwOGFkaXF6a2N4
Published 20 Aug 2024 15:28
PSC08 | Transaction MzQzMjc2NzQwNmFkaXF6a2N4
Published 20 Aug 2024 14:55
PSC07 | Transaction MzQzMjc2Njg3MGFkaXF6a2N4
Published 20 Aug 2024 14:50
Company registered at Companies House
LightOx develops light activated chemotherapy designed to treat early-stage oral cancer, with its technology also having applications as a research tool in imaging, therapeutics and assay binding.
2 Patents
None
1 May 2024 to 31 Oct 2025
The management of wounds is a "silent epidemic" that is challenging health services worldwide. The NHS treated 3.8 million patients with a wound in 2017/18, translating to a burden of \>£8.3billion. A major factor that influences the successful healing of a wound is an infection by colonising microbes. Untreated infections prevent healing, but can also sp...
1 Apr 2024 to 31 Mar 2025
The management of wounds is a "silent epidemic" that is challenging health services worldwide. The NHS treats 2.2 million patients with a chronic wound, the management of which costs at least £5.6 billion each year. A major factor inhibiting wound healing is infections caused by colonising microbes. Untreated infections prevent healing and often spread; t...
1 Dec 2023 to 31 May 2025
The management of wounds is a "silent epidemic" that is challenging health services worldwide. The NHS treated 3.8 million patients with a wound in 2017/18, translating to a burden of \>£8.3billion. A major factor that influences the healing of a wound is an infection by colonising microbes. Untreated infections prevent healing, but can also spread furthe...
1 May 2023 to 30 Apr 2025
Oral cancers are the 14th most common cancer in the UK. Around 50% of patients die within 5-years of diagnosis, whilst a reliance on invasive surgery (used in 95% of cases) means that survivors are left with severe life-long impacts affecting swallowing, eating and speech. The number of cases of oral cancer is increasing, particularly in those aged 50+, w...
1 Mar 2023 to 31 Aug 2023
LightOx are a drug development company based in Newcastle upon Tyne that has made its light-activated products, known as LightOx Probes, available to other researchers to enable them to understand biological processes that occur in a cell. LightOx has shown that their Probe molecules are capable of emitting fluorescence when they are activated by light, a...
1 Jan 2022 to 31 Mar 2022
LightOx are a drug development company based in the North East of England that has made its light-activated products available to other researchers to develop and understand the biological processes that occur in a cell. These "LightOx Probes" act to show biological researchers the importance of specific cell functions and the mechanisms that cells use to...
1 Jun 2020 to 30 Nov 2020
no public description
1 Dec 2019 to 30 Jun 2021
LightOx looks to advance the scientific field of biological imaging using fluorescence by developing novel agents that have intrinsic chemical properties for targeting cell subtypes and intracellular organelles. The experimental basis of this comes from a background of 15 years of research within university institutes and are now being undertaken by the c...
